Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mismatch Repair Deficient Solid Malignant Tumor”

40 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 40 results

Early research (Phase 1)Active Not RecruitingNCT03589339
What this trial is testing

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Who this might be right for
RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more
Nanobiotix 145
Not applicableNot Yet RecruitingNCT07689812
What this trial is testing

Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Carcinoma)+12 more
Natera, Inc. 920
Testing effectiveness (Phase 2)WithdrawnNCT04001101
What this trial is testing

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Who this might be right for
Microsatellite Instability HighMismatch Repair DeficiencyColorectal Cancer
University of Colorado, Denver
Testing effectiveness (Phase 2)Active Not RecruitingNCT04969887
What this trial is testing

Combination Immunotherapy in Rare Cancers Under InvesTigation

Who this might be right for
Advanced Biliary Tract CancerNeuroendocrine TumorsFemale Reproductive System Neoplasm+1 more
Olivia Newton-John Cancer Research Institute 240
Testing effectiveness (Phase 2)Looking for participantsNCT07127822
What this trial is testing

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMSI-H Cancer
Peking University 106
Testing effectiveness (Phase 2)Ended earlyNCT04393454
What this trial is testing

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Who this might be right for
Metastatic dMMR Solid CancerSolid TumorCancer+1 more
Albert Einstein College of Medicine 6
Early research (Phase 1)Study completedNCT03053466
What this trial is testing

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Who this might be right for
Solid TumorMicrosatellite InstabilityMismatch Repair Deficiency+1 more
Apollomics (Australia) Pty. Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06580574
What this trial is testing

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Who this might be right for
Gastric CancerColon CancerMSI-H+1 more
Peking University 34
Testing effectiveness (Phase 2)UnknownNCT04326829
What this trial is testing

QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

Who this might be right for
Advanced Malignant Tumor
Qilu Pharmaceutical Co., Ltd. 86
Testing effectiveness (Phase 2)Looking for participantsNCT04114136
What this trial is testing

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Who this might be right for
MelanomaNSCLCHepatocellular Carcinoma+5 more
Dan Zandberg 72
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110
Testing effectiveness (Phase 2)Ended earlyNCT04547101
What this trial is testing

AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Who this might be right for
MSI-H/dMMR Solid Tumor
Akeso 6
Not applicableNot Yet RecruitingNCT07374809
What this trial is testing

IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

Who this might be right for
Endometrial Carcinoma (EC)pMMRDMMR Cancer
European Institute of Oncology 50
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Looking for participantsNCT06898450
What this trial is testing

Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc. 134
Testing effectiveness (Phase 2)UnknownNCT04521075
What this trial is testing

A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

Who this might be right for
Melanoma Stage IVUnresectable MelanomaNSCLC Stage IV
Ella Therapeutics Ltd 42
Not applicableStudy completedNCT06020651
What this trial is testing

Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside

Who this might be right for
Renal Cell CarcinomaBladder CancerMSI-H Cancer+1 more
Institut Mutualiste Montsouris 39
Testing effectiveness (Phase 2)WithdrawnNCT06400264
What this trial is testing

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT03941574
What this trial is testing

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Who this might be right for
MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech 108
Next Page